Ventyx Biosciences (NASDAQ:VTYX) Stock, Quote.Headers.trade-ideas

Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Wall Street

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CGTX

LIPO

NLSP

VERO

VTVT

VTYX

Dow Edges Lower; Ventyx Biosciences Shares Plummet

movers image

Movers

AVXL

BMRC

CERO

COMM

COUR

CPTN

CTRI

IART

ITRG

LGVN

LUXH

MESO

NIPG

NISN

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Image33

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

Ventyx Biosciences Inc

The ongoing debate over cannabis rescheduling continues to stir discussions within the industry, with many wondering what it will mean for the future <a href="https://www.benzinga.com/cannabis">of cannabis regulation.</a>
Recent actions by federal agencies have prompted hope that rescheduling may occur within the next year, but the path remains unclear. According to Gary Santo, the CEO of Rx Green Technologies, the process is far from simple.
<h3 class="wp-block-heading">Untangling the Road to Cannabis Rescheduling</h3>
Santo, who will be speaking at the upcoming <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a>, discussed the complexity of rescheduling during a recent interview. He explained that while the rescheduling process has seen movement, it is not just a matter of waiting for a decision. "There's more than just hope behind this rescheduling process. We've already seen significant movement—40,000 public comments, requests for hearings—so it's no longer just talk," he said.
Despite this progress, Santo urged caution, stating that the rescheduling timeline could extend longer than many in the industry expect. "In 12 months, I don't think it's unrealistic to say within 12 months, I don't think they can just keep rolling this along," he said, acknowledging that federal agencies must address several complex factors before making any final decision.
<h3 class="wp-block-heading">The Difference Between Rescheduling and Descheduling</h3>
Santo also weighed in on the critical distinction between rescheduling and descheduling cannabis. Both options are being discussed, but each has implications for the industry. "You could deschedule it; you can reschedule it. And there are so many moving parts that need to be addressed throughout different parts of the government and also with working with the states," he explained. These moving parts include various regulatory hurdles and coordination across multiple federal and state agencies, complicating the process.
He also cautioned that the simultaneous efforts to push for different outcomes—rescheduling, descheduling, or other reforms—could create confusion. "Sometimes I wonder if having all these different initiatives—the shotgun approach—is more harmful than helpful. Everyone's chasing different outcomes, and that might slow down actual progress," Santo observed, suggesting that a more focused approach might yield quicker results.
<h3 class="wp-block-heading">What the Industry Can Expect</h3>
As the cannabis industry awaits further developments, many operators are left wondering how rescheduling—or descheduling—will ultimately affect them. He stressed that while progress is being made, the actual impact of these regulatory changes could take years to materialize.
"Rescheduling has already set things in motion. There's no turning back now; a conclusion has to be reached," he said, adding that the industry should prepare for a potentially lengthy process.
Santo's analysis highlights the importance of understanding the full scope of regulatory changes rather than expecting immediate results. As the industry evolves, operators and investors must prepare for the challenges and opportunities that rescheduling may bring.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly from top executives, investors, advocates, and policymakers at the 19th <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference </a>in Chicago this Oct. 8-9. Get your tickets now before prices surge by following this <a href="https://www.benzinga.com/events/cannabis-conference/">link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/09/40930071/thailands-new-cannabis-bill-stricter-rules-but-marijuana-remains-legal">Thailand&#8217;s New Cannabis Bill: Stricter Rules, But Marijuana Remains Legal</a></li>
</ul>
Image: Nicky from Pixabay

Cannabis

Events

Exclusives

Interview

'No Turning Back Now': Cannabis Rescheduling Gains Momentum, Expert Offers Timeline

Asset Sales

GEVO

Gevo Sells $20M In Investment Tax Credits From NW Iowa RNG Facility, Generating $17M In Net Proceeds To Drive Clean Energy Investment

GDHG

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

RBC Capital analyst Paul Treiber reiterates Altus Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AIF#TSX">AIF</a>) with a Sector Perform and maintains C$55 price target.

Price Target

Reiteration

Analyst Ratings

TSX:AIF

RBC Capital Reiterates Sector Perform on Altus Group, Maintains C$55 Price Target

Meet <a href="https://www.benzinga.com/personal-finance/24/06/39528195/larry-finks-proposal-for-saving-social-security-is-to-attract-more-older-americans-to-work-until">Laurence &#8220;Larry&#8221; Douglas Fink</a>, the CEO of BlackRock, one of the most powerful companies in the world. At 71, Fink has built a financial empire managing approximately $10 trillion in assets, including a hefty $20 billion in Bitcoin.&nbsp;
Although relatively low-profile, Larry&#8217;s influence in the financial world is unmatched. His net worth is $1.2 billion, and BlackRock controls a massive 357,509 Bitcoin – an astounding number for any company, let alone one rooted in traditional finance.
Don't Miss:
<ul>
<li>If you invested $100 in DOGE when Elon Musk first tweeted about it in 2019,<a href="https://www.benzinga.com/money/etoro-doge"> here&#8217;s how much you&#8217;d have today</a>.</li>
<li>Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a></li>
</ul>
Larry&#8217;s rise to power began in 1988 when he cofounded BlackRock with seven others. Over the years, he's worn multiple hats – chairman of the board, executive and leadership committees, and co-chair of the global client committee.
But things truly kicked off for Larry and BlackRock after the 2007-2008 financial crisis. The U.S. government turned to BlackRock to help steer the country from economic disaster, sparking rumors about Larry's close connections with officials like Tim Geithner, Obama's first Treasury Secretary.
Trending: According to Cathie Wood, holding 6 Ethereum (ETH) could make you a millionaire,<a href="https://www.benzinga.com/money/adv-6eth"> here&#8217;s why it can be true</a>.
In 2009, BlackRock acquired Barclays Global Investors, cementing its status as the largest asset manager in the world. However, Larry Fink's name rarely makes headlines, except for when he's invited on CNBC.&nbsp;
He's made a comfortable living running the firm – earning $23.6 million in 2010 and $36 million in 2021. By 2016, BlackRock had already ballooned to $5 trillion in assets and employed over 12,000 people in 27 countries.
Larry's influence extends beyond BlackRock. In 2018, Forbes named him the 28th most powerful person in the world. But there's something more recent that's turned heads beyond the money and influence: Larry's about-face on Bitcoin.
Trending: If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?
Just a few years ago, Larry was a staunch Bitcoin critic. Back in 2017, he famously quipped, &#8220;Bitcoin just shows you how much demand for money laundering there is in the world.&#8221; In 2018, he even described Bitcoin as "an index of money laundering" and doubted its legitimacy. &#8220;Bitcoin is not a real investment,&#8221; he said, citing its market volatility as a major red flag.
So, what changed? It's simple – market demand. Over the years, <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40656496/trump-got-orange-pilled-in-puerto-rico-bitcoiners-100-million-pitch-that-changed-everythin">Bitcoin </a>has evolved from a niche asset to a mainstream financial instrument with a market cap that rivals the world's largest companies. Larry recognized that BlackRock's institutional clients wanted in, and he couldn't afford to let competitors like Fidelity get ahead.
Trending: 1 in 4 Americans own a share of Bitcoin according to NASDAQ,<a href="https://www.benzinga.com/money/nasdaq-1in4-adv"> how many people got started through this free crypto faucet?</a>
But convincing BlackRock's board wasn't easy. The largest shareholder, Vanguard, has a strong anti-crypto stance, with its CEO recently doubling down on their aversion to Bitcoin. So, how did Larry get the board on board with a $13.7 billion Bitcoin purchase? He framed Bitcoin not as just a cryptocurrency but as part of a larger financial revolution.&nbsp;
He pitched Bitcoin as a hedge against inflation, especially given rising global tensions and threats of de-dollarization. Larry's vision wasn't just about Bitcoin but about tokenizing real-world assets, which he believes will redefine finance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." These high-yield real estate notes that pay 7.5% &#8211; 9%</a> make earning passive income easier than ever.</li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Larry Fink Defies BlackRock's Largest Shareholder To Make A Bold Bet On Bitcoin – Here's How He Shifted Their Stance Against The Odds

RBC Capital analyst Drew McReynolds maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and raises the price target from C$51 to C$53.

TSX:BCE

RBC Capital Maintains Sector Perform on BCE, Raises Price Target to C$53

Roth MKM analyst Eric Handler maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Neutral and maintains $154 price target.

Roth MKM Maintains Neutral on Electronic Arts, Maintains $154 Price Target

A six-figure campaign event at a luxury Georgia resort aimed at <a href="https://www.benzinga.com/topic/florida-cannabis" target="_blank" rel="noopener">opposing Florida's cannabis</a> and abortion amendments ended up losing money rather than generating a profit.
What Happened: The Ron <a href="https://www.benzinga.com/markets/cannabis/24/06/39279951/desantis-new-freedom-fund-has-2-stated-goals-defeat-cannabis-legalization-and-abortion-amendment">DeSantis-affiliated Florida Freedom Fund</a>, formed in late-May with the stated goal of defeating cannabis legalization and restoring abortion access, "blew through nearly $116,000 between Aug. 31 and Sept. 6, even though it raised just over $41,000 in the same time," <a href="https://floridapolitics.com/archives/696216-ron-desantis-tied-committee-spends-big-on-georgia-ritz-carlton-retreat-as-it-fights-pot-abortion-initiatives-in-florida/">reported</a> Florida Politics. Most of that, about $115,000, went to cover costs at the Ritz-Carlton in Georgia. This spending constitutes over a third of the campaign's total expenditures since it launched. 
The cannabis legalization initiative, known as Amendment 3, is set to go before Florida voters in <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d" target="_blank" rel="noopener">the upcoming November elections</a>.
Despite the lavish spending, the committee raised just over $41,000 during the same period, marking the second time its expenditures outpaced contributions. Both the Florida Freedom Fund and Keep Florida Clean, another anti-amendment group linked to DeSantis, have struggled with more spending than fundraising since September. Keep Florida Clean spent more than $286,000 in the same period but raised just $1,600.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h2 class="wp-block-heading">Pro-Cannabis Committee Is Flush: Millions Keep Coming In</h2>
Meanwhile, Amendment 3, which is now the best-funded cannabis legalization amendment in American history, has no shortage of cash on hand. Led by the <a href="https://drupal-cloudfront.benzinga.com/topic/smart-safe-florida">Smart &amp; Safe Florida</a> committee, the amendment received $90.44 million through Aug. 30, <a href="https://news.ballotpedia.org/2024/09/18/florida-amendment-3-exceeds-previous-records-for-marijuana-legalization-campaign-contributions/">according to Ballotpedia</a>.
As of Sept. 6, Florida's largest medical marijuana company, Trulieve Cannabis Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>), had contributed $87.77 million in cash and in-kind contributions to the Smart &amp; Safe committee since 2022, reported News Service of Florida, citing a state database.
DeSantis <a href="https://www.benzinga.com/markets/cannabis/24/09/40926862/desantis-targets-one-big-weed-company-funding-floridas-legalization-campaign-cites-corporate-int">lashed out</a> recently at Trulieve, calling the company a corporate monopoly that seeks to corner the cannabis market.
Read More: <a href="https://www.benzinga.com/markets/cannabis/24/09/40926862/desantis-targets-one-big-weed-company-funding-floridas-legalization-campaign-cites-corporate-int">DeSantis Targets &#8216;One Big Weed Company&#8217; Funding Florida&#8217;s Legalization Campaign, Citing &#8216;Corporate Interests&#8217;</a>
<h2 class="wp-block-heading">Anti-Cannabis Committees Having Trouble Keeping Up</h2>
Both the Florida Freedom Fund and Keep Florida Clean committees are chaired by James Uthmeier, DeSantis' chief of staff and former campaign manager when the governor ran for president. As of Sept. 6, the Florida Freedom Fund had a little more than $3.4 million remaining in cash. Keep Florida Clean had just over $3.9 million, noted Florida Politics.
While fundraising has been lackluster, the Florida Freedom Fund received several notable donations, including $25,000 from Next Generation Energy Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NGMC#OTC">NGMC</a>) and $10,000 from a Pompano Beach retiree. The outlet noted that the committee continues to rely heavily on a mid-August  $12 million donation from Citadel CEO Ken Griffin.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40923340/trump-says-yes-to-legal-cannabis-in-florida-but-hometown-palm-beach-says-no-thanks-to-weed-shops">Trump Says Yes To Legal Cannabis In Florida, But Hometown Palm Beach Says No Thanks To Weed Shops</a></li>
</ul>
Photo by Hvoenok-and-GOR-Photos

Politics

NGMC

TCNNF

TRUL

DeSantis-Backed Anti-Cannabis PACs 'Blew Through' $116K At Fundraiser, While Pro-Pot Group Holds $90M War Chest

Guidance

Corning Says Implementing Price Increases In Display Technologies And Expects To Deliver Segment Net Income Of $900M-$950M In 2025, And To Maintain Net Income Margin Of 25%

WLDS

Wearable Devices Unveils Mudra Band Gesture Control For Apple Watch, Offering AI-Powered, Touchless Operation For Hands-Free Convenience And Enhanced Accessibility

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.corning.com%2Fworldwide%2Fen.html&amp;esheet=54124384&amp;newsitemid=20240918594823&amp;lan=en-US&amp;anchor=Corning+Incorporated&amp;index=1&amp;md5=428e64b43c9d60ea476cf7923800b0b0">Corning Incorporated</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) will host a meeting today at its optical fiber facility in Concord, North Carolina, with investors and industry analysts to provide significant updates to its "Springboard" plan to add more than $3 billion in annualized sales with strong incremental profit and cash flow in the next three years.
Wendell P. Weeks, chairman and chief executive officer, said,"I'm very pleased with the progress we have made on our ‘Springboard' plan to add more than $3 billion in annualized sales by 2026. The plan leads to an improving return profile, with profits growing significantly faster than sales. Today, we are sharing our Springboard operating-margin target of 20% by the end of 2026."
Weeks continued, "We are implementing price increases in Display Technologies and expect to deliver segment net income of $900 million to $950 million in 2025, and to maintain net income margin of 25%. Additionally, our positive momentum in Optical Communications continues – Enterprise sales are expected to grow by more than 40% year over year in the third quarter, driven by the continued strong adoption of our generative AI products."
Ed Schlesinger, executive vice president and chief financial officer, said, "Our second-quarter results and third-quarter guidance put us well ahead of our ‘Springboard' plan run rate. In the third quarter, we continue to expect sales of $3.7 billion and EPS of $0.50 to $0.54."
Today, Corning management will lead investors through a tour of the company's – and the world's – largest and lowest cost optical-fiber production facility. During the visit, leadership will highlight the company's unique competitive advantage and industry and technology leadership – which enables Corning to capture the significant growth opportunity outlined in its Springboard plan.

Corning Provides Update On Key Milestones In 'Springboard' Plan To Add More Than $3B In Annualized Sales, And Shares Operating-Margin Target Of 20% By End Of 2026; Sees Q3 Expected Sales Of $3.7B (Est. $3.71B); And EPS Of $0.50-$0.54 (Est. $0.53)

WIIM

CRKN

Crown Electrokinetics shares are trading higher after the company announced it secured a $10 million contract for lead pipe inspection.

RBC Capital analyst Greg Pardy reiterates Imperial Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#TSX">IMO</a>) with a Sector Perform and maintains C$99 price target.

TSX:IMO

RBC Capital Reiterates Sector Perform on Imperial Oil, Maintains C$99 Price Target

Contracts

Crown Electrokinetics' Element 82 Division Secures $10M Contract For Lead Pipe Inspection, Work To Begin In Late October 2024

Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) is gearing up for the holiday season with new initiatives<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40931888/walmart-unveils-its-holiday-plans-with-early-shopping-deals-and-affordable-meals" rel="noreferrer noopener"> aimed at convenient shopping habits</a>.
Leading the charge is the return of its inflation-free Thanksgiving meal, now priced lower than last year, set to launch on October 14.
This year, the retailer also introduced a convenient &#8220;buy one, give one&#8221; donation feature, allowing customers to easily contribute meals to those in need.
According to Deloitte&#8217;s annual holiday retail <a target="_blank" href="https://www2.deloitte.com/us/en/pages/about-deloitte/articles/press-releases/Deloitte-Holiday-Retail-Sales-2024-2025.html" rel="noreferrer noopener">forecast</a>, holiday retail sales are expected to rise between 2.3% and 3.3% in 2024. In 2023, holiday sales had a growth rate of 4.3% during the same timeframe.
In the aftermath of COVID, the biggest retailers in the U.S. have captured a significantly larger portion of retail growth, according to a Forbes <a target="_blank" href="https://www.forbes.com/sites/jasongoldberg/2024/05/29/the-holiday-2024-shopping-season-will-be-unlike-any-other/" rel="noreferrer noopener">report </a>released in May.
The report highlighted that Walmart and Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) account for about 38% of every additional retail sales dollar, making growth difficult for most other retailers and creating considerable uncertainty.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com//node/40902098" rel="noreferrer noopener">Evaluating Walmart Against Peers In Consumer Staples Distribution &amp; Retail Industry</a>
&#8220;We&#8217;ve worked hard to lower prices across our most exciting assortment ever,&#8221; said Latriece Watkins, executive vice president and chief merchandising officer, Walmart U.S.
Walmart is starting holiday savings events, with the first Walmart Holiday Deals event scheduled from October 8 to October 13.
Walmart said it is also expanding its delivery services, reaching an additional 12 million households, which will provide enhanced speed and convenience for customers looking to shop from the comfort of their homes.
Earlier this week, Sam&#8217;s Club, the&nbsp;$86 billion&nbsp;division of&nbsp;Walmart, introduced a fresh workforce compensation plan, which boosted pay for close to 100,000 frontline associates and provided guidance for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40900897/sams-club-reimagines-workforce-compensation-launches-new-plan-focused-on-providing-more-predictabl" rel="noreferrer noopener">longer-term financial futures</a>.
More engaged workers proved productive, offered better service, and were more likely to stay, especially as competition heated up in the retail space.
Price Action: WMT shares are trading higher by 0.08% to $79.10 premarket at last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40906505/walmart-division-sams-club-raises-wages-for-hourly-associates-a-strategic-move-to-stay-ahead-in-" target="_blank" rel="noreferrer noopener">Walmart Division Sam&#8217;s Club Raises Wages For Hourly Associates: A Strategic Move To Stay Ahead In Retail</a></li>
</ul>

Equities

Media

General

AMZN

Walmart Steps Up Holiday Game, Inflation-Free Thanksgiving Meal Returns

Roth MKM analyst Scott Searle maintains Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) with a Buy and raises the price target from $3.5 to $4.5.

GNSS

Roth MKM Maintains Buy on Genasys, Raises Price Target to $4.5

SHEL

Shell Announces Early Participation Results And Increases Maximum Old Notes Accepted In Exchange Offers To $12B, Extends Early Participation Premium To All Holders Until October 3, 2024

APLD

ARBK

BITF

BTBT

BTDR

CIFR

CLSK

COIN

FUFU

HIVE

IREN

MARA

MSTR

RIOT

WULF

Shares of crypto-linked stocks are trading higher after the Fed's Wednesday decision to cut rates by 50 basis points.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) is going to go higher, adding that <a href="https://www.benzinga.com/quote/WFC">it's a &#8220;winner.&#8221;</a>
On Sept. 17, the San Francisco-based bank launched specialized Application Programming Interfaces (APIs) for its Commercial Banking clients, expanding its API portfolio. 
These APIs offer real-time data access aimed at boosting sales, improving liquidity, reducing credit risk, and cutting expenses for floorplan and channel finance clients <a href="https://www.benzinga.com/markets/equities/24/09/40903846/wells-fargo-launches-new-apis-to-boost-efficiency-and-productivity-details">across several industries.</a>
&#8220;It's had too big a move up,&#8221; Cramer said when asked about Iron Mountain Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>). &#8220;Let's move on.&#8221;
On Aug. 1, Iron Mountain reported better-than-expected second-quarter financial results and issued FY24 AFFO guidance above estimates. Also, the company increased its quarterly dividend.
Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) is a &#8220;cold&#8221; stock, Cramer said.
On Sept. 17, the company inked a multi-year, multi-million-dollar contract with Nebraska Medicine. As per the deal, Palantir will utilize its Artificial Intelligence Platform (AIP) to enhance healthcare through <a href="https://www.benzinga.com/markets/equities/24/09/40898997/palantirs-ai-powers-nebraska-medicine-inks-multi-million-dollar-deal-to-advance-patient-care">transformative technologies</a>.
The &#8220;Mad Money&#8221; host recommended buying PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>). &#8220;That stock is a good one, rate increase or no,&#8221; he added.
On Sept. 12, B of A Securities analyst Ross Fowler reinstated PG&amp;E with a Buy and announced a $24 price target.
Price Action:
<ul>
<li>Iron Mountain shares gained 0.5% to settle at $116.45 on Wednesday.</li>
<li>Wells Fargo shares fell 0.5% to close at $54.26 during the session.</li>
<li>Palantir shares fell 0.2% to close at $36.38 during Wednesday's session.</li>
<li>PG&amp;E shares fell 1.8% to settle at $19.51.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40927530/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></li>
</ul>
Image: Wikimedia Commons

Long Ideas

PLTR

Jim Cramer: This Utilities Stock Is A Buy, Calls Wells Fargo A 'Winner'

GOLD

RGLD

SAND

SSRM

Shares of precious metals stocks are trading higher as gold and silver rise after the Fed on Wednesday cut rates by 50 basis points.

These are the weight loss drug stocks with the most upside - SA Sentiment Survey

Ventyx Biosciences' mid-stage trial of Crohn's disease treatment did not meet main goal

Ventyx Biosciences falls after trial for Crohn's disease treatment did not meet main goal

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today. The company's shares closed last ...

LifeSci Capital Keeps Their Buy Rating on Ventyx Biosciences (VTYX)

Ventyx Biosciences GAAP EPS of -$0.45

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price...

Ventyx Biosciences: A Cautious Hold Amid Intensifying Competition in Obesity Treatment Market

Piper Sandler analyst Yasmeen Rahimi assigned a Buy rating to Ventyx Biosciences (VTYX – Research Report) today and set a price target of $21.00. T...

Piper Sandler Issues a Buy Rating on Ventyx Biosciences (VTYX)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ventyx Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtyx-stock-quote/">VTYX</a>) just reported results for the second quarter of 2024.<ul><li>Ventyx Biosciences reported earnings per share of -45 cents. This was above the analyst estimate for EPS of -57 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vtyx-stock-earnings-ventyx-biosciences-for-q2-of-2024/">VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024

Ventyx Biosciences CFO departs

Ventyx Biosciences (VTYX) has issued an announcement. Ventyx Biosciences, Inc. has appointed Roy M. Gonzales as the interim principal financial off...

Ventyx Biosciences Announces Executive Financial Officer Changes

ABBV

AMGN

CRBP

GPCR

VKTX

ZLDPF

Press Releases

VENTYX STOCK NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Reminded to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Legal

VENTYX INSIDER TRADING ALERT: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details

VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details

Health Care

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn's Disease

Earnings

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Management

Ventyx Biosciences Announces Departure of Chief Financial Officer

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Ventyx Biosciences

Ventyx Biosciences (VTYX) Forecast

Ventyx Biosciences (NASDAQ:VTYX) Stock, Quote.Headers.trade-ideas